摘要
目的比较全身化疗加或不加力尔凡对小细胞肺癌的疗效、不良反应及免疫功能的变化。方法将56例小细胞肺癌患者以随机方式分为治疗组CE(卡铂、VP-16)方案化疗并用力尔凡和对照组单用CE方案化疗。结果①治疗组缓解率85.7%,对照组71.4%(P>0.05),中位缓解期分别为10.6月、8.4月;②治疗组治疗后和治疗前相比CD4及CD4/CD8显著升高(P<0.05),而对照组则相反,两组差异显著(P<0.05);③不良反应:治疗组白细胞下降53.6%,对照组达92.9%(P<0.05)。结论力尔凡与化疗同时应用治疗小细胞肺癌,疗效有所提高;可增强细胞的免疫功能,对化疗引起的白细胞下降有保护作用。
Objective To compare the response rate, toxicity and immunological effect of CE regimen with or without Lifein for small cell lung cancer （ SCLC ）. Methods 56 patients with SCLC were randomly divided into treatment group and control group receiving CE （ Carboplatin, Etoposide VP- 16） regimen plus Lifein or CE regimen alone respectively. Results ①The partial response rate was 85.7% in treatment group and 71.4% in control group （ P 〉0. 05）. The median response duration was 10. 6 months and 8.4 months in these two groups respeclivcly. ②the levels of CD4 and CD4/CD8 were significantly increased in the treatment group whereas no change in the control group （P 〈0.05）. ③Toxicity： 15 patients of 28 （53.6%） in treatment group who underwent leucocyte count reduction, which was observed in 26 padents of 28 （92. 9% ）in control group （ P 〈 0.05 ）. Conclusion Lifein has some functions of potentiating the antitumour effect of chemotherapy, enhancing the immunity functions of the patients treated with chemotherapy. Reversing the decreasing of leucocyte count induced by chemotherapy, and the tolerance is well.
出处
《医药论坛杂志》
2006年第18期26-27,共2页
Journal of Medical Forum
